Impact of carboxylesterase 1 genetic polymorphism on trandolapril activation in human liver and the pharmacokinetics and pharmacodynamics in healthy volunteers

Trandolapril, an angiotensin‐converting enzyme inhibitor prodrug, needs to be activated by carboxylesterase 1 (CES1) in the liver to exert its intended therapeutic effect. A previous in vitro study demonstrated that the CES1 genetic variant G143E (rs71647871) abolished CES1‐mediated trandolapril act...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Xinwen, Her, Lucy, Xiao, Jingcheng, Shi, Jian, Wu, Audrey H., Bleske, Barry E., Zhu, Hao‐Jie
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2021
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8301577/
https://www.ncbi.nlm.nih.gov/pubmed/33660934
http://dx.doi.org/10.1111/cts.12989

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8301577/
https://www.ncbi.nlm.nih.gov/pubmed/33660934
http://dx.doi.org/10.1111/cts.12989

Ejemplares similares